JP2009515819A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009515819A5 JP2009515819A5 JP2008534618A JP2008534618A JP2009515819A5 JP 2009515819 A5 JP2009515819 A5 JP 2009515819A5 JP 2008534618 A JP2008534618 A JP 2008534618A JP 2008534618 A JP2008534618 A JP 2008534618A JP 2009515819 A5 JP2009515819 A5 JP 2009515819A5
- Authority
- JP
- Japan
- Prior art keywords
- scfv
- blood
- brain
- receptor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000008499 blood brain barrier function Effects 0.000 claims 14
- 210000001218 blood-brain barrier Anatomy 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 8
- 239000008280 blood Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 210000004556 brain Anatomy 0.000 claims 6
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical group 0.000 claims 5
- 108060003951 Immunoglobulin Proteins 0.000 claims 4
- 102000018358 immunoglobulin Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 208000014644 Brain disease Diseases 0.000 claims 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 3
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 3
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 3
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims 2
- 102000003746 Insulin Receptor Human genes 0.000 claims 2
- 108010001127 Insulin Receptor Proteins 0.000 claims 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims 2
- 102000011965 Lipoprotein Receptors Human genes 0.000 claims 2
- 108010061306 Lipoprotein Receptors Proteins 0.000 claims 2
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 102000005861 leptin receptors Human genes 0.000 claims 2
- 108010019813 leptin receptors Proteins 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 230000001717 pathogenic effect Effects 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/245,710 | 2005-10-07 | ||
| US11/245,546 US8142781B2 (en) | 2005-10-07 | 2005-10-07 | Fusion proteins for blood-brain barrier delivery |
| US11/245,546 | 2005-10-07 | ||
| US11/245,710 US8053569B2 (en) | 2005-10-07 | 2005-10-07 | Nucleic acids encoding and methods of producing fusion proteins |
| PCT/US2006/038587 WO2007044323A2 (en) | 2005-10-07 | 2006-09-28 | Fusion proteins for blood-brain barrier delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014116085A Division JP6320179B2 (ja) | 2005-10-07 | 2014-06-04 | 血液脳関門輸送用融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009515819A JP2009515819A (ja) | 2009-04-16 |
| JP2009515819A5 true JP2009515819A5 (enExample) | 2009-11-12 |
| JP5941607B2 JP5941607B2 (ja) | 2016-06-29 |
Family
ID=37943316
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008534618A Active JP5941607B2 (ja) | 2005-10-07 | 2006-09-28 | 血液脳関門輸送用融合タンパク質 |
| JP2014116085A Active JP6320179B2 (ja) | 2005-10-07 | 2014-06-04 | 血液脳関門輸送用融合タンパク質 |
| JP2016100640A Expired - Fee Related JP6283711B2 (ja) | 2005-10-07 | 2016-05-19 | 血液脳関門輸送用融合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014116085A Active JP6320179B2 (ja) | 2005-10-07 | 2014-06-04 | 血液脳関門輸送用融合タンパク質 |
| JP2016100640A Expired - Fee Related JP6283711B2 (ja) | 2005-10-07 | 2016-05-19 | 血液脳関門輸送用融合タンパク質 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8142781B2 (enExample) |
| EP (2) | EP3118218A3 (enExample) |
| JP (3) | JP5941607B2 (enExample) |
| AU (1) | AU2006302589A1 (enExample) |
| CA (1) | CA2625293C (enExample) |
| WO (1) | WO2007044323A2 (enExample) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| JP4903036B2 (ja) | 2003-01-06 | 2012-03-21 | アンジオケム・インコーポレーテッド | 血液脳関門を通過する担体としてのアプロチニンおよび類似体 |
| US7485706B2 (en) * | 2003-07-30 | 2009-02-03 | The Board Of Trustees Of The Leland Stanford Junior University | Neurodegenerative protein aggregation inhibition methods and compounds |
| WO2007009229A1 (en) | 2005-07-15 | 2007-01-25 | Angiochem Inc. | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| US8124095B2 (en) * | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US7981417B2 (en) * | 2006-06-07 | 2011-07-19 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting anti-bodies |
| WO2008022349A2 (en) * | 2006-08-18 | 2008-02-21 | Armagen Technologies, Inc. | Agents for blood-brain barrier delivery |
| US20080200441A1 (en) * | 2007-02-14 | 2008-08-21 | University Of Southern California | Estrogen receptor modulators associated pharmaceutical compositions and methods of use |
| US20090011040A1 (en) * | 2007-05-02 | 2009-01-08 | Naash Muna I | Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US20100197012A1 (en) * | 2007-06-05 | 2010-08-05 | National Tsing Hua University | Application of RNA Interference Targeting dhfr Gene, to Cell for Producing Secretory Protein |
| CA2694762A1 (en) | 2007-07-27 | 2009-02-05 | Armagen Technologies, Inc. | Methods and compositions for increasing alpha-l-iduronidase activity in the cns |
| WO2009127072A1 (en) | 2008-04-18 | 2009-10-22 | Angiochem Inc. | Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use |
| CA2740317A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| WO2010043047A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| US9914754B2 (en) | 2008-12-05 | 2018-03-13 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| AU2009327267A1 (en) | 2008-12-17 | 2011-07-14 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| EP2408474B1 (en) * | 2009-03-18 | 2019-06-26 | Armagen, Inc. | Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins |
| DK2417156T3 (en) | 2009-04-07 | 2015-03-02 | Roche Glycart Ag | Trivalent, bispecific antibodies |
| ES2729261T3 (es) | 2009-04-20 | 2019-10-31 | Angiochem Inc | Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2 |
| CA2764777A1 (en) * | 2009-06-11 | 2010-12-16 | Angiochem Inc. | Fusion proteins for delivery of gdnf and bdnf to the central nervous system |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| WO2011000095A1 (en) | 2009-07-02 | 2011-01-06 | Angiochem Inc. | Multimeric peptide conjugates and uses thereof |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| KR101553740B1 (ko) | 2009-08-17 | 2015-09-17 | 트라콘 파마수티칼즈, 인코포레이티드 | 항엔도글린 항체 및 항ｖｅｇｆ 제제를 사용한 암 치료를 위한 병용 요법 |
| HUE044865T2 (hu) | 2009-10-09 | 2019-11-28 | Armagen Inc | Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére |
| EP3252068B1 (en) | 2009-10-12 | 2025-07-02 | Larry J. Smith | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
| US8415306B2 (en) * | 2010-05-27 | 2013-04-09 | Janssen Biotech, Inc. | Insulin-like growth factor 1 receptor binding peptides |
| EP2603221A4 (en) * | 2010-08-13 | 2014-02-26 | Univ Georgetown | GGF2 AND METHOD FOR ITS APPLICATION |
| EA034333B1 (ru) | 2010-11-30 | 2020-01-29 | Дженентек, Инк. | Варианты антитела для переноса соединения через гематоэнцефалический барьер |
| WO2012075340A2 (en) | 2010-12-01 | 2012-06-07 | Alderbio Holdings Llc | Anti-ngf compositions and use thereof |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| CN103403025B (zh) | 2011-02-28 | 2016-10-12 | 弗·哈夫曼-拉罗切有限公司 | 单价抗原结合蛋白 |
| JP5764677B2 (ja) | 2011-02-28 | 2015-08-19 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 抗原結合タンパク質 |
| US10227387B2 (en) * | 2011-05-18 | 2019-03-12 | Children's Hospital Medical Center | Targeted delivery of proteins across the blood-brain barrier |
| ES2714999T3 (es) * | 2011-09-24 | 2019-05-31 | Csl Behring Gmbh | Terapia de combinación que usa inmunoglobulina e inhibidor de C1 |
| ES2983576T3 (es) | 2011-12-02 | 2024-10-23 | Armagen Inc | Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC |
| EA201491920A1 (ru) * | 2012-05-21 | 2016-03-31 | Дженентек, Инк. | Способы повышения безопасности транспорта через гематоэнцефалический барьер |
| WO2014004465A1 (en) | 2012-06-25 | 2014-01-03 | The Brigham And Women's Hospital, Inc. | Targeted therapeutics |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| UA115789C2 (uk) | 2012-09-05 | 2017-12-26 | Трейкон Фармасутікалз, Інк. | Композиція антитіла до cd105 та її застосування |
| DK2968503T3 (en) | 2013-03-15 | 2018-12-03 | Intrinsic Lifesciences Llc | ANTI-HEPCIDIN ANTIBODIES AND APPLICATIONS THEREOF |
| EP4324480A3 (en) | 2013-05-20 | 2024-05-08 | F. Hoffmann-La Roche AG | Anti-transferrin receptor antibodies and methods of use |
| US10906981B2 (en) * | 2013-07-19 | 2021-02-02 | The Regents Of The University Of California | Compositions and methods related to structures that cross the blood brain barrier |
| AU2014312190A1 (en) | 2013-08-28 | 2016-02-18 | Bioasis Technologies Inc. | CNS-targeted conjugates of antibodies |
| WO2015091130A1 (en) * | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Method for improving the recombinant production of soluble fusion polypeptides |
| US10370692B2 (en) * | 2013-12-20 | 2019-08-06 | Hoffmann-La Roche Inc. | Recombinant polypeptide production methods |
| BR112016015589A2 (pt) * | 2014-01-06 | 2017-10-31 | Hoffmann La Roche | módulos de trânsito monovalentes para a barreira hematoencefálica |
| EP3197915A4 (en) | 2014-09-22 | 2018-12-19 | Intrinsic Lifesciences LLC | Humanized anti-hepcidin antibodies and uses thereof |
| CA2966905A1 (en) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
| EP3221362B1 (en) | 2014-11-19 | 2019-07-24 | F.Hoffmann-La Roche Ag | Anti-transferrin receptor antibodies and methods of use |
| PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
| US10538589B2 (en) | 2015-01-14 | 2020-01-21 | Armagen Inc. | Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| IL302486A (en) | 2015-06-24 | 2023-06-01 | Hoffmann La Roche | Antibodies against the transnephrine receptor with adapted affinity |
| EA039366B1 (ru) | 2015-06-24 | 2022-01-19 | Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. | Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер |
| AU2016283344B2 (en) * | 2015-06-24 | 2022-08-04 | Jcr Pharmaceuticals Co., Ltd. | Fusion protein containing BDNF |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| JP6657392B2 (ja) | 2015-10-02 | 2020-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗ヒトｃｄ２０／ヒトトランスフェリン受容体抗体及び使用方法 |
| US11752315B1 (en) | 2016-10-07 | 2023-09-12 | Carlos A. Hakim | Method of treating normal pressure hydrocephalus |
| CA3040687A1 (en) * | 2016-10-14 | 2018-04-19 | Childrens' Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
| EP3561058B1 (en) | 2016-12-26 | 2025-07-23 | JCR Pharmaceuticals Co., Ltd. | Fusion protein including bdnf |
| JP6956741B2 (ja) | 2016-12-26 | 2021-11-02 | Ｊｃｒファーマ株式会社 | 血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体 |
| US12000843B2 (en) | 2017-01-17 | 2024-06-04 | Children's Medical Center Corporation | Compositions and methods for diagnosing and treating peroxisomal diseases |
| CN108467428A (zh) * | 2018-03-26 | 2018-08-31 | 江苏中新医药有限公司 | 一种清除rhNGF中N端截短及异常变异体的方法 |
| BR112020020646A2 (pt) * | 2018-04-11 | 2021-02-23 | Salubris Biotherapeutics, Inc. | composições de proteína de fusão recombinante de neuregulina-1 (nrg-1) humana e métodos de uso destas |
| EP3833689A4 (en) * | 2018-08-07 | 2022-05-25 | Armagen, Inc. | METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CENTRAL NERVOUS SYSTEM OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE AND PALMITOYL-PROTEIN THIOESTERASE 1 |
| WO2020142587A1 (en) * | 2019-01-03 | 2020-07-09 | The Board Of Trustees Of The University Of Illinois | Method and kit for treating a neurodegenerative disease |
| BR112022000876A2 (pt) | 2019-07-19 | 2022-04-26 | Oncoresponse Inc | Anticorpos imunomoduladores e métodos de uso destes |
| WO2021030781A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with antisense oligonucleotides targeting kras |
| WO2021030769A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicles with nras antisense oligonucleotides |
| EP4013877A1 (en) | 2019-08-14 | 2022-06-22 | Codiak BioSciences, Inc. | Extracellular vesicle-aso constructs targeting stat6 |
| CA3147365A1 (en) | 2019-08-14 | 2021-02-18 | Joanne LIM | Extracellular vesicle-nlrp3 antagonist |
| WO2021030780A1 (en) | 2019-08-14 | 2021-02-18 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting cebp/beta |
| US20230241089A1 (en) | 2019-09-25 | 2023-08-03 | Codiak Biosciences, Inc. | Sting agonist comprising exosomes for treating neuroimmunological disorders |
| WO2021184020A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Methods of treating neuroinflammation |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| US20230220068A1 (en) | 2020-06-05 | 2023-07-13 | Codiak Biosciences, Inc. | Anti-transferrin extracellular vesicles |
| CA3128035A1 (en) | 2020-08-13 | 2022-02-13 | Bioasis Technologies, Inc. | Combination therapies for delivery across the blood brain barrier |
| EP4265715A4 (en) | 2021-01-12 | 2024-11-27 | JCR Pharmaceuticals Co., Ltd. | Nucleic acid molecule containing incorporated gene encoding fused protein of ligand and protein having physiological activity |
| WO2022178149A2 (en) | 2021-02-17 | 2022-08-25 | Codiak Biosciences, Inc. | Extracellular vesicle-nlrp3 antagonist |
| CN112851759B (zh) * | 2021-02-23 | 2022-12-27 | 李婧炜 | 噬菌体展示技术筛选可穿越血-脑脊液屏障的多肽 |
| CA3238914A1 (en) | 2021-11-19 | 2023-05-25 | Jcr Pharmaceuticals Co., Ltd. | Peptide having affinity for human transferrin receptor |
| EP4455290A4 (en) | 2021-12-28 | 2025-11-26 | Japan Chem Res | Fusion protein of an anti-transferrin receptor antibody and a bioactive protein for safe gene therapy |
| WO2024080305A1 (ja) * | 2022-10-11 | 2024-04-18 | Ｊｃｒファーマ株式会社 | 血清アルブミンと生理活性を有する蛋白質との融合蛋白質 |
| IL322412A (en) | 2023-02-07 | 2025-09-01 | Japan Chem Res | A peptide with high affinity for the human transferrin receptor |
| WO2025035176A1 (en) * | 2023-08-14 | 2025-02-20 | The Bionics Institute Of Australia | A fusion protein |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5180820A (en) * | 1989-08-30 | 1993-01-19 | Barde Yves Alain | Brain-derived neurotrophic factor |
| US5229500A (en) * | 1989-08-30 | 1993-07-20 | Regeneron Pharmaceuticals, Inc. | Brain derived neurotrophic factor |
| US5977307A (en) * | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5672683A (en) * | 1989-09-07 | 1997-09-30 | Alkermes, Inc. | Transferrin neuropharmaceutical agent fusion protein |
| US5154924A (en) * | 1989-09-07 | 1992-10-13 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| US6329508B1 (en) * | 1989-09-07 | 2001-12-11 | Alkermes, Inc. | Transferrin receptor reactive chimeric antibodies |
| TW279133B (enExample) * | 1990-12-13 | 1996-06-21 | Elan Med Tech | |
| US5527288A (en) * | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US6060069A (en) * | 1991-05-20 | 2000-05-09 | Dura Pharmaceuticals, Inc. | Pulmonary delivery of pharmaceuticals |
| US6287792B1 (en) * | 1991-06-17 | 2001-09-11 | The Regents Of The University Of California | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology |
| MX9205293A (es) * | 1991-09-20 | 1993-05-01 | Syntex Sinergen Neuroscience J | Factores neurotrofico derivado del glial |
| JPH06228199A (ja) * | 1992-11-27 | 1994-08-16 | Takeda Chem Ind Ltd | 血液脳関門通過可能なペプチド結合体 |
| US5997501A (en) * | 1993-11-18 | 1999-12-07 | Elan Corporation, Plc | Intradermal drug delivery device |
| EP0706799B1 (en) * | 1994-09-16 | 2001-11-14 | MERCK PATENT GmbH | Immunoconjugates II |
| US5656284A (en) * | 1995-04-24 | 1997-08-12 | Balkin; Michael S. | Oral transmucosal delivery tablet and method of making it |
| DE69630798T2 (de) * | 1995-09-19 | 2004-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Aerosolzusammensetzungen |
| US5837231A (en) * | 1996-06-27 | 1998-11-17 | Regents Of The University Of Minnesota | GM-CSF administration for the treatment and prevention of recurrence of brain tumors |
| AU8269898A (en) * | 1997-06-27 | 1999-01-19 | Regents Of The University Of California, The | Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor |
| US6482923B1 (en) * | 1997-09-17 | 2002-11-19 | Human Genome Sciences, Inc. | Interleukin 17-like receptor protein |
| US6016800A (en) * | 1997-10-24 | 2000-01-25 | Century; Theodore J. | Intrapulmonary aerosolizer |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| DE69839969D1 (de) * | 1997-12-11 | 2008-10-16 | Alza Corp | Vorrichtung zur verbesserung des transdermalen flusses von medikamenten |
| US6348210B1 (en) * | 1998-11-13 | 2002-02-19 | Alza Corporation | Methods for transdermal drug administration |
| US6375975B1 (en) * | 1998-12-21 | 2002-04-23 | Generex Pharmaceuticals Incorporated | Pharmaceutical compositions for buccal and pulmonary application |
| US6284262B1 (en) * | 1999-01-26 | 2001-09-04 | Virgil A. Place | Compact dosage unit for buccal administration of a pharmacologically active agent |
| US7309687B1 (en) * | 1999-04-13 | 2007-12-18 | The Kenneth S. Warren Institute, Inc. | Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin |
| CZ299516B6 (cs) * | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| US6372250B1 (en) * | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
| US6696274B2 (en) * | 2000-05-03 | 2004-02-24 | Supratek Pharma, Inc. | Ligand for enhancing oral and CNS delivery of biological agents |
| US7078376B1 (en) * | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| WO2002055736A2 (en) * | 2000-12-04 | 2002-07-18 | Univ California | Antisense imaging of gene expression of the brain in vivo |
| RU2003125637A (ru) * | 2001-02-06 | 2005-03-10 | Мерк Патент ГмбХ (DE) | Модифицированный нейтрофический фактор выделенный из мозга человека (bdnf) с уменьшенной иммуногенностью |
| JP4202250B2 (ja) * | 2001-07-25 | 2008-12-24 | バイオマリン ファーマシューティカル インコーポレイテッド | 血液脳関門輸送を調節するための組成物および方法 |
| US7053202B2 (en) * | 2001-10-19 | 2006-05-30 | Millennium Pharmaceuticals, Inc. | Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor |
| JP4219152B2 (ja) * | 2002-10-31 | 2009-02-04 | ヤマハマリン株式会社 | 船舶推進機におけるオイル交換時期警報装置 |
| US6850492B2 (en) * | 2002-11-22 | 2005-02-01 | Nokia Corporation | Method and system for enabling a route and flow table update in a distributed routing platform |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20050142141A1 (en) * | 2002-11-27 | 2005-06-30 | Pardridge William M. | Delivery of enzymes to the brain |
| US7294704B2 (en) * | 2003-08-15 | 2007-11-13 | Diadexus, Inc. | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk |
| EP1548031A1 (en) * | 2003-12-22 | 2005-06-29 | Dubai Genetics FZ-LLC | Nature-identical erythropoietin |
| US20060222668A1 (en) * | 2005-04-01 | 2006-10-05 | Wellspring Pharmaceutical Corporation | Stannsoporfin compositions, drug products and methods of manufacture |
| US8741260B2 (en) * | 2005-10-07 | 2014-06-03 | Armagen Technologies, Inc. | Fusion proteins for delivery of GDNF to the CNS |
| US8124095B2 (en) | 2005-10-07 | 2012-02-28 | Armagen Technologies, Inc. | Fusion proteins for delivery of erythropoietin to the CNS |
| US8142781B2 (en) * | 2005-10-07 | 2012-03-27 | Armagen Technologies, Inc. | Fusion proteins for blood-brain barrier delivery |
| JP2010510794A (ja) * | 2006-11-28 | 2010-04-08 | ハナル ファーマシューティカル カンパニー リミテッド | 修飾型エリスロポエチンポリペプチド及びこの治療用用途 |
| JP6083219B2 (ja) * | 2012-12-06 | 2017-02-22 | 富士通セミコンダクター株式会社 | プラズマフラッドガン及びイオン注入装置 |
-
2005
- 2005-10-07 US US11/245,546 patent/US8142781B2/en not_active Expired - Lifetime
- 2005-10-07 US US11/245,710 patent/US8053569B2/en not_active Expired - Lifetime
-
2006
- 2006-09-28 WO PCT/US2006/038587 patent/WO2007044323A2/en not_active Ceased
- 2006-09-28 CA CA2625293A patent/CA2625293C/en active Active
- 2006-09-28 EP EP16171496.9A patent/EP3118218A3/en not_active Withdrawn
- 2006-09-28 JP JP2008534618A patent/JP5941607B2/ja active Active
- 2006-09-28 EP EP06825389A patent/EP1945259A4/en not_active Ceased
- 2006-09-28 AU AU2006302589A patent/AU2006302589A1/en not_active Abandoned
-
2014
- 2014-06-04 JP JP2014116085A patent/JP6320179B2/ja active Active
-
2016
- 2016-05-19 JP JP2016100640A patent/JP6283711B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515819A5 (enExample) | ||
| Courade et al. | Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau | |
| Wouters et al. | Identification and in vivo characterization of a brain-penetrating nanobody | |
| US10174105B2 (en) | Use of VHH antibodies for the preparation of peptide vectors for delivering a substance of interest and their applications | |
| CN112236452A (zh) | 检测和治疗阿尔茨海默氏病的基于抗体的方法 | |
| JP2025026843A5 (enExample) | ||
| JP2010539921A5 (enExample) | ||
| HRP20180516T1 (hr) | Humanizirana protutijela specifična za protofibrilni oblik amiloidnog-beta peptida | |
| JP2010506596A5 (enExample) | ||
| UA99701C2 (ru) | Человеческое моноклональное антитело, которое специфически связывается с лигандом-1 запрограммированной гибели клеток (pd-l1) | |
| JP2010502207A5 (enExample) | ||
| JP2003524587A5 (enExample) | ||
| JP2014503198A5 (enExample) | ||
| JP2015509097A5 (enExample) | ||
| JP2013529070A5 (enExample) | ||
| JP2016525502A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| US11098096B2 (en) | Alzheimer Aβ peptide binding polypeptide | |
| JP2018518940A5 (enExample) | ||
| JP2013535190A5 (enExample) | ||
| Elmer et al. | Gene delivery of a modified antibody to Aβ reduces progression of murine Alzheimer’s disease | |
| Geerts et al. | Analysis of clinical failure of anti-tau and anti-synuclein antibodies in neurodegeneration using a quantitative systems pharmacology model | |
| Ferrantelli et al. | Engineered extracellular vesicles/exosomes as a new tool against neurodegenerative diseases | |
| Niazi et al. | Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders | |
| Tang et al. | Peptide-functionalized nanoparticles for brain-targeted therapeutics |